STOCK TITAN

[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:

  • Grant of 75,000 employee stock options
  • Exercise price set at $7.43 per share
  • Options expire on June 19, 2035
  • Vesting schedule: 1/48th of shares vest monthly from June 20, 2025

This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.

Il Chief Medical Officer di RAPT Therapeutics, William Ho, ha ricevuto una nuova concessione di opzioni su azioni il 20 giugno 2025. I dettagli della transazione sui titoli derivati sono i seguenti:

  • Concessione di 75.000 opzioni azionarie per dipendenti
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Le opzioni scadono il 19 giugno 2035
  • Programma di maturazione: 1/48 delle azioni matura mensilmente a partire dal 20 giugno 2025

Questa comunicazione Form 4, firmata dal procuratore Rodney Young, rappresenta una concessione standard di compensazione azionaria a un dirigente chiave. La durata decennale dell’opzione suggerisce una strategia di fidelizzazione a lungo termine per la posizione di Chief Medical Officer. Il piano di maturazione mensile su quattro anni è in linea con le consuete pratiche del settore per la retribuzione degli executive.

El Director Médico de RAPT Therapeutics, William Ho, recibió una nueva concesión de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacción de valores derivados incluyen:

  • Concesión de 75,000 opciones sobre acciones para empleados
  • Precio de ejercicio establecido en $7.43 por acción
  • Las opciones expiran el 19 de junio de 2035
  • Calendario de adquisición: 1/48 de las acciones se adquiere mensualmente desde el 20 de junio de 2025

Este formulario 4, firmado por el apoderado Rodney Young, representa una concesión estándar de compensación en acciones a un ejecutivo clave. La concesión de opciones a diez años sugiere una estrategia de retención a largo plazo para el puesto de Director Médico. El calendario de adquisición mensual durante cuatro años se alinea con las prácticas habituales de la industria para la compensación ejecutiva.

RAPT Therapeutics의 최고 의료 책임자 William Ho2025년 6월 20일에 새로운 스톡 옵션을 부여받았습니다. 파생 증권 거래 세부 사항은 다음과 같습니다:

  • 직원 스톡 옵션 75,000주 부여
  • 행사가격은 주당 $7.43로 설정
  • 옵션 만료일은 2035년 6월 19일
  • 베스팅 일정: 2025년 6월 20일부터 매월 1/48씩 베스팅

본 Form 4 제출 서류는 대리인 Rodney Young이 서명했으며, 핵심 임원에 대한 표준 주식 보상 부여를 나타냅니다. 10년간의 옵션 부여는 최고 의료 책임자 직책에 대한 장기 유지 전략을 시사합니다. 4년간 매월 베스팅 일정은 임원 보상에 대한 업계 일반 관행과 일치합니다.

Le directeur médical de RAPT Therapeutics, William Ho, a reçu une nouvelle attribution d’options d’achat d’actions le 20 juin 2025. Les détails de la transaction sur titres dérivés sont les suivants :

  • Attribution de 75 000 options d’achat d’actions aux employés
  • Prix d’exercice fixé à 7,43 $ par action
  • Expiration des options le 19 juin 2035
  • Calendrier d’acquisition : 1/48 des actions acquises mensuellement à partir du 20 juin 2025

Ce dépôt Formulaire 4, signé par le mandataire Rodney Young, représente une attribution standard de rémunération en actions à un cadre clé. L’attribution d’options sur dix ans suggère une stratégie de rétention à long terme pour le poste de directeur médical. Le calendrier d’acquisition mensuel sur quatre ans est conforme aux pratiques habituelles de l’industrie en matière de rémunération des cadres.

Der Chief Medical Officer von RAPT Therapeutics, William Ho, erhielt am 20. Juni 2025 eine neue Aktienoptionszuteilung. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gewährung von 75.000 Mitarbeiteraktienoptionen
  • Ausübungspreis von 7,43 $ pro Aktie
  • Optionen laufen am 19. Juni 2035 ab
  • Vesting-Zeitplan: 1/48 der Aktien wird monatlich ab dem 20. Juni 2025 freigegeben

Diese Form 4-Meldung, unterzeichnet vom Bevollmächtigten Rodney Young, stellt eine standardmäßige Aktienvergütung für einen wichtigen Führungskraft dar. Die zehnjährige Optionslaufzeit deutet auf eine langfristige Bindungsstrategie für die Position des Chief Medical Officer hin. Der monatliche Vesting-Zeitplan über vier Jahre entspricht den üblichen Branchenpraktiken für die Vergütung von Führungskräften.

Positive
  • None.
Negative
  • None.

Il Chief Medical Officer di RAPT Therapeutics, William Ho, ha ricevuto una nuova concessione di opzioni su azioni il 20 giugno 2025. I dettagli della transazione sui titoli derivati sono i seguenti:

  • Concessione di 75.000 opzioni azionarie per dipendenti
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Le opzioni scadono il 19 giugno 2035
  • Programma di maturazione: 1/48 delle azioni matura mensilmente a partire dal 20 giugno 2025

Questa comunicazione Form 4, firmata dal procuratore Rodney Young, rappresenta una concessione standard di compensazione azionaria a un dirigente chiave. La durata decennale dell’opzione suggerisce una strategia di fidelizzazione a lungo termine per la posizione di Chief Medical Officer. Il piano di maturazione mensile su quattro anni è in linea con le consuete pratiche del settore per la retribuzione degli executive.

El Director Médico de RAPT Therapeutics, William Ho, recibió una nueva concesión de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacción de valores derivados incluyen:

  • Concesión de 75,000 opciones sobre acciones para empleados
  • Precio de ejercicio establecido en $7.43 por acción
  • Las opciones expiran el 19 de junio de 2035
  • Calendario de adquisición: 1/48 de las acciones se adquiere mensualmente desde el 20 de junio de 2025

Este formulario 4, firmado por el apoderado Rodney Young, representa una concesión estándar de compensación en acciones a un ejecutivo clave. La concesión de opciones a diez años sugiere una estrategia de retención a largo plazo para el puesto de Director Médico. El calendario de adquisición mensual durante cuatro años se alinea con las prácticas habituales de la industria para la compensación ejecutiva.

RAPT Therapeutics의 최고 의료 책임자 William Ho2025년 6월 20일에 새로운 스톡 옵션을 부여받았습니다. 파생 증권 거래 세부 사항은 다음과 같습니다:

  • 직원 스톡 옵션 75,000주 부여
  • 행사가격은 주당 $7.43로 설정
  • 옵션 만료일은 2035년 6월 19일
  • 베스팅 일정: 2025년 6월 20일부터 매월 1/48씩 베스팅

본 Form 4 제출 서류는 대리인 Rodney Young이 서명했으며, 핵심 임원에 대한 표준 주식 보상 부여를 나타냅니다. 10년간의 옵션 부여는 최고 의료 책임자 직책에 대한 장기 유지 전략을 시사합니다. 4년간 매월 베스팅 일정은 임원 보상에 대한 업계 일반 관행과 일치합니다.

Le directeur médical de RAPT Therapeutics, William Ho, a reçu une nouvelle attribution d’options d’achat d’actions le 20 juin 2025. Les détails de la transaction sur titres dérivés sont les suivants :

  • Attribution de 75 000 options d’achat d’actions aux employés
  • Prix d’exercice fixé à 7,43 $ par action
  • Expiration des options le 19 juin 2035
  • Calendrier d’acquisition : 1/48 des actions acquises mensuellement à partir du 20 juin 2025

Ce dépôt Formulaire 4, signé par le mandataire Rodney Young, représente une attribution standard de rémunération en actions à un cadre clé. L’attribution d’options sur dix ans suggère une stratégie de rétention à long terme pour le poste de directeur médical. Le calendrier d’acquisition mensuel sur quatre ans est conforme aux pratiques habituelles de l’industrie en matière de rémunération des cadres.

Der Chief Medical Officer von RAPT Therapeutics, William Ho, erhielt am 20. Juni 2025 eine neue Aktienoptionszuteilung. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gewährung von 75.000 Mitarbeiteraktienoptionen
  • Ausübungspreis von 7,43 $ pro Aktie
  • Optionen laufen am 19. Juni 2035 ab
  • Vesting-Zeitplan: 1/48 der Aktien wird monatlich ab dem 20. Juni 2025 freigegeben

Diese Form 4-Meldung, unterzeichnet vom Bevollmächtigten Rodney Young, stellt eine standardmäßige Aktienvergütung für einen wichtigen Führungskraft dar. Die zehnjährige Optionslaufzeit deutet auf eine langfristige Bindungsstrategie für die Position des Chief Medical Officer hin. Der monatliche Vesting-Zeitplan über vier Jahre entspricht den üblichen Branchenpraktiken für die Vergütung von Führungskräften.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HO WILLIAM

(Last) (First) (Middle)
C/O RAPT THERAPEUTICS, INC.
561 ECCLES AVENUE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $7.43 06/20/2025 A 75,000 (1) 06/19/2035 Common Stock 75,000 $0 75,000 D
Explanation of Responses:
1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.
/s/ Rodney Young, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to RAPT Therapeutics' Chief Medical Officer William Ho in June 2025?

William Ho was granted 75,000 employee stock options on June 20, 2025, with an exercise price of $7.43 per share. These options expire on June 19, 2035.

What is the vesting schedule for William Ho's RAPT stock options granted in June 2025?

The stock options vest monthly over 4 years, with 1/48th of the shares vesting each month following the vesting commencement date of June 20, 2025.

Who filed the Form 4 for RAPT Therapeutics (RAPT) on June 28, 2025?

The Form 4 was filed for William Ho, RAPT Therapeutics' Chief Medical Officer, and was signed by Rodney Young as Attorney-in-Fact on June 24, 2025.

What is the total value of RAPT stock options granted to William Ho in June 2025?

William Ho received options to purchase 75,000 shares of RAPT common stock at an exercise price of $7.43 per share. The options were granted at $0 cost to Ho as part of his compensation package.
Rapt Therapeutics, Inc.

NASDAQ:RAPT

RAPT Rankings

RAPT Latest News

RAPT Latest SEC Filings

RAPT Stock Data

122.86M
12.71M
0.49%
96.43%
1.99%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO